Optimi Health announces the opening of Canada’s largest GMP-grade psilocybin cultivation operating, including a 10,000 square foot production facility.

Incannex Healthcare announces a “shareholder loyalty option” to raise A$23.6 million (US$16.5 million). For every two shares purchased, investors will receive a “piggyback option”.

Private psychedelics company, Terran Biosciences announces a drug development partnership with Sanofi S.A. for the development and commercialization of two late-stage CNS drugs.

Minera Alamos’ “new” model for successful gold mining in the 21st century has a very retro flair to it.

Several major new deals in the psychedelics industry already in 2022 suggest that the industry could be moving on to its next phase of evolution.

Dozens of psychedelic drugs to research. Several “generations” of R&D ahead. To say that we’re early in the game with psychedelic drug research is an understatement.

Tryp Therapeutics closes the second tranche of its recently announced private placement for gross proceeds of CAD$3 million. Units are priced at CAD$0.15.

The “Shark Tank” star predicts three of the biggest psychedelic companies will merge into a mega corporation, but our resident Psychedelic Investor wonders: Should they?

Cybin announces a new clinical partner as it prepares for its Phase 1/2a clinical trial for CYB003.

Inflation is rapidly eroding our purchasing power and consuming our wealth. Here is a powerful antidote for investors.